ATXN1 and colorectal carcinoma: In 2017, the CRC-SCA initiated an NIH-funded 5-years project, “Clinical Trial Readiness for SCA1 and SCA3 (READISCA).” READISCA (NCT03487367) is the first US–European collaborative SCA project and focuses on premanifest and early-stage subjects of SCA1 and SCA3 mutation carriers.